Search Results for: www stemcell tv

StemCellTV Daily Report-January 24, 2012 – Video

Posted: January 27, 2012 at 10:04 pm

24-01-2012 10:19 Stem cells may soon be used in penile reconstruction for men that have erectile dysfunction or Peyronie's disease.

Posted in Stem Cells | Comments Off

StemCellTV Talks to Morrie Ruffin of Alliance for Regenerative Medicine at Meeting on the Mesa – Video

Posted: December 10, 2011 at 11:27 am

William Bruyea, host of StemCellTV talks to Morrie Ruffin, co-founder and managing director of Alliance for Regenerative Medicine at the Meeting on the Mesa partnering forum at Sanford Consortium in La Jolla, CA. Morrie discusses regenerative medicine, stem cells and development.

Original post:
StemCellTV Talks to Morrie Ruffin of Alliance for Regenerative Medicine at Meeting on the Mesa - Video

Posted in Regenerative Medicine | Comments Off

StemCellTV Talks to Elona Baum of the California Institute of Regenerative Medicine – Video

Posted: December 10, 2011 at 11:27 am

William Bruyea, host of StemCellTV talks to Elona Baum of the California Institute for Regenerative Medicine (CIRM) about the Meeting on the Mesa Partnering Event at Sanford Consortium and co-sponsoring with Alliance for Regenerative Medicine (ARM).

See the article here:
StemCellTV Talks to Elona Baum of the California Institute of Regenerative Medicine - Video

Posted in Regenerative Medicine | Comments Off

StemCellTV Talks to Morrie Ruffin of Alliance for Regenerative Medicine at Meeting on the Mesa – Video

Posted: December 10, 2011 at 10:19 am

Visit link:
StemCellTV Talks to Morrie Ruffin of Alliance for Regenerative Medicine at Meeting on the Mesa - Video

Posted in Regenerative Medicine | Comments Off

StemCellTV Talks to Elona Baum of the California Institute of Regenerative Medicine – Video

Posted: December 10, 2011 at 2:23 am

Continue reading here:
StemCellTV Talks to Elona Baum of the California Institute of Regenerative Medicine - Video

Posted in Regenerative Medicine | Comments Off

StemCellTV Talks to Michael Werner of Alliance for Regenerative Medicine at Meeting on the Mesa – Video

Posted: December 9, 2011 at 9:40 pm

William Bruyea, host of StemCellTV talks to Michael Werner, co-founder and executive director of Alliance for Regenerative Medicine at the Meeting on the Mesa partnering forum at Sanford Consortium in La Jolla, CA. Michael discusses regenerative medicine, stem cells and development, and stem cell regulation.

See original here:
StemCellTV Talks to Michael Werner of Alliance for Regenerative Medicine at Meeting on the Mesa - Video

Posted in Cell Medicine | Comments Off

StemCellTV Report – Bartolo Colon Stem Cell Treatment on NBC News Miami – Video

Posted: December 9, 2011 at 1:35 am

StemCellTV Special Report - Dr. Purita of Boca Raton, Florida reports to NBC News Miami regarding stem cell treatments to NY Yankees pitcher Bartolo Colon to heal his injured elbow and shoulder.

View post:
StemCellTV Report - Bartolo Colon Stem Cell Treatment on NBC News Miami - Video

Posted in Stem Cell Treatments | Comments Off

Alabama Stem Cells | Stem Cell TV

Posted: September 12, 2019 at 1:44 pm

The first commercial product from Hampton Creeks new clean meat production platform will likely be in the avian family, director of cellular agriculture Eitan Fischer told FoodNavigator-USA as the company best known for its work on plant-based proteins unveiled ambitious plans to explore the animal variety.

Fischer was speaking to us after Hampton Creek founder Josh Tetrick posted anarticle on linkedin explaining that producing 'clean' or 'cultured' meat (by culturing cells without raising or slaughtering animals) and plant-based meat/eggs, both stemmed from a desire to find kinder and more sustainable alternatives to industrial animal farming.

His comments came as Dr Eric Schulze, senior scientist at Memphis Meats probably the best-known clean meat company told delegates at the IFT show this week that his company aims to launch premium-priced clean meat products in high-end restaurants in 2019, and more mass market products in grocery stores in 2021.

Poultry will likely be first to market in late 2018, Fischer told us: We believe the first product released commercially will likely be in the avian family.

Longer term, however, the plan is to build a multi-species, multi-product platform spanning the entire range of meat and seafood, he said.

We haven't solved the meat and seafood problem until we are able to make all of these products.

Asked how long Hampton Creek had been working on the technology, and what kinds of scientists were working on the project, he said: We have been working on this for over a year. Many members of our 59-person R&D team are involved, between our molecular team, our analytical chemistry team, our process team, and our product development team.

We also supplemented the significant in-house expertise we had previously with additional, more specific specialists such as scientists with stem cell biology, medicine, and tissue engineering backgrounds.

"We believe that clean meat can be evaluated and regulated within existing regulatory frameworks... Clean meat is a food, not a drug, not a new animal drug or a food additive..." [read more on this at FoodNavigator-USA next week..]

Rebecca Cross, counsel,Davis Wright Tremaine LLP

We think its unlikely that families in Alabama (or anywhere in the world) will consistently choose plant-based alternatives over chicken, beef, pork, and seafood Over the past year, weve started the early work of expanding our platform to solve the technical challenges of scalable clean meat.

With plants providing nutrients for animal cells to grow, we believe we can produce meat and seafood that is over 10x more efficient than the worlds highest volume slaughterhouse.

Imagine choosing between a similarly priced pound of clean high-grade bluefin tuna belly or conventional tilapia from underwater traps. Or clean A5 Kobe beef versus conventional sirloin (corn-fed and confined). Our approach will be transparent and unquestionably safe, free of antibiotics and have a much lower risk of foodborne illness. The right choice will be obvious.

Weve started the process of licensing our discoveries to the worlds largest food manufacturers and, in the years ahead, well do the same with the worlds largest meat and seafood companies.

Josh Tetrick, founder and CEO, Hampton Creek

Fischer would not say what kind of stem cells the company is using, or whether the plan is to first proliferate cells in a stir tank bioreactor and then transfer them to a larger perfusion type bioreactor where they will mature and differentiate in to the different cell types (fat, muscle, connective tissue).

However, he confirmed that, We are building a platform that enables us to produce cells of different types including muscle, fat, and others, in a bioreactor-based process.

As for the go-to-market strategy, he said: We are exploring various options for the initial release but are most focused on how to get the costs down to parity or below current meat prices. We haven't truly solved the meat and seafood problem until we've done so.

The company has not said what it is using as a growth medium (the nutrient-rich bath the cells need to grow) but said its expertise in plant-based products had enabled it to develop a viable vegan alternative to animal serum.

"The entry of a billion-dollar company into the clean meat market sector is a vote of confidence in the technology, and we hope that Hampton Creek will be the first of many major food companies to dive into this incrediblypromisingfield."

Bruce Friedrich, executive director, The Good Food Institute

In a mapping document penned by the Good Food Institute earlier this month, the authors predicted that clean meat would likely come to market in phases, with the first products perhaps hybrids combining clean meat and plant-based meat; followed by ground meat products (nuggets, burgers); and finally those mimicking steaks or chicken breasts, which present significantly greater technical challenges.

The first products that come to market may be hybrid products wherein clean meat is included as a part of plant-based products that essentially require only cell lines, media, and proliferative bioreactors to come to fruition.

They add: The next commercial products will likely be ground meat mimics, where scaffolding can be minimal; more complex structures requiring vascularization or perfusion bioreactors are not necessarily required.

Finally, more structured tissues like those mimicking steaks or chicken breasts will require research and development in all of the areas outlined above. Thus, a consideration of target product(s) should drive the R&D focus.

Speaking at a webinar hosted by the GFI on June 8, Dr Specht added: "I think there's a lot of evidence to suggest that consumers would be interested in hybrid products," citing the success of products already on the market that feature combinations of regular meat and plant-based ingredients, such as mushroom blend burgers and sausages with 40% meat, which are marketing on a health and sustainability platform, and can also be more affordable.

"The phrase 'clean meat' is similar to 'clean energy' in that it immediately communicates important aspects of the technologyboth the environmental benefits and the decrease in food-borne pathogens and drug residues."

Bruce Friedrich, executive director, The Good Food Institute

This Good Food Institute schematic illustrates one conception of the clean meat production process at scale. The first stage is proliferation of the cells, followed by a differentiation and maturation stage where cells are seeded onto scaffolds and allowed to mature into the cell types required for meat.

Clean meat production begins with obtaining cell lines for the desired animal species (eg. chicken, pork, beef) that behave in a predictable way through many generations, while maintaining an unlimited capacity to reproduce/divide (ie. immortalized cell lines).

Next you have to proliferate cells, perhaps in a stir tank bioreactor where you might suspend your cells in the growth medium (both Hampton Creek and Memphis Meats claim to have found viable alternatives to animal serum read more about that HERE ) and stir them and keep them warm.

As for the next stage, where you want to encourage the creation of an organized pattern of muscle, fat, and connective tissue cells, this would probably require seeding onto scaffolding and then differentiating into the various cell types, the stage at which you get real fat cells forming and the muscle cells forming into fibers to give that authentic meaty texture, said Dr Specht.

Here, the scaffolding would need to be something that is subsumed within the final meat product so it would have to be made out of something that is degradable over time, or something edible that would not impact the taste or safety of the final product such as cellulose or collagen, she said.

To accommodate three-dimensional growth, the scaffolds must exhibit porosity for perfusing nutrient media [the nutrients have to be able to reach the cells], she added. Alternatively, they must support vascularization of the tissue itself, i.e., the formation of a network of vessels to allow nutrients to permeate the tissue. Several production methods, including 3D printing and spun-fiber platforms, allow fine-tuning of pore size and microstructures within the scaffold.

"Once you get to the scaffold stage, that area is less explored and has not yet been demonstrated at scale."

Interested in clean meat?

GFI senior scientist Dr Liz Specht will give delegates at FOOD VISION USA 2017 the lowdown on clean meat, while Alex Lorestani will explain how Geltor is producing gelatin without animals. See the latest speaker list HERE .

See the original post here:Hampton Creek to enter clean meat market in 2018: 'We are building a multi-species, multi-product platform' - FoodNavigator-USA.com

Read the original post:
Alabama Stem Cells | Stem Cell TV

Posted in Alabama Stem Cells | Comments Off

New Mexico Stem Cells | Stem Cell TV

Posted: September 12, 2019 at 1:42 pm

Stem cell therapy can be described as a means or process by which stem cells are used for the prevention, treatment or the cure of diseases. Stem cells are a special kind of cells that have features other types of cells dont have. As an illustration, stem cells are capable of proliferation. This implies that they can develop into any type of cell, and grow to start performing the functions of the tissue. In addition, they can regenerate. This means they can multiply themselves. This is most important when a new tissue has to be formed. Also, they modulate immune reactions. This has made them useful for the treatment of autoimmune diseases, especially those that affect the musculoskeletal system such as rheumatoid arthritis, systemic lupus erythematosus and so on. Stem cells can be derrived from different sources. They can be extracted from the body, and in some specific parts of the body. This includes the blood, bone marrow, umbilical cord in newborns, adipose tissue, and from embryos. There are 2 main types of stem cell transplant. These are autologous stem cell transplant, and allogeneic stem cell transplant. The autologous stem cell transplant means that stem cells are extracted from the patient, processed, and then transplanted back to the patient, for therapeutic purposes. On the other hand, allogeneic stem cell transplant means the transplant of stem cells or from another individual, known as the donor, to another person, or recipient. Some treatments must be given to the receiver to prevent any cases of rejections, and other complications. The autologous is usually the most preferred type of transplant because of its almost zero side effects. Below are some of the stem cell treatments. Our goal is to provide education, research and an opportunity to connect with Stem Cell Doctors, as well as provide stem cell reviews

Adipose Stem Cell TreatmentsAdipose stem cell treatment is one of the most commonly used. This is because large quantities of stem cells can be derrived from them. According to statistics, the number of stem cells in adipose tissue are usually hundreds of times higher than what can be obtained from other sources, such as the bone marrow stem cells. Adipose stem cells have taken the center stage in the world of stem cell therapy. Apart from the ease that comes with the harvesting of these cells from the adipose tissue, they also have some special features, that separates them from other types of cells. Adipose stem cells are capable of regulating and modulating the immune system. This includes immune suppression, which is important for the treatment of autoimmune diseases. In addition, adipose stem cells can differentiate to form other types of cells. Some of them include the bone forming cells, cardiomyocytes, and cells of the nervous system.

This process can be divided into four parts. These are

Stem cell joint injection is fast becoming the new treatment of joint diseases. Stem cells derived from bone marrow, adipose and mesenchymal stem cells are the most commonly used. The stem cells are injected into the joints, and they proceed to repair and replace the damaged tissues. The cells also modulate the inflammatory process going on. Overall, stem cell joint injections significantly reduce the recovery time of patients and also eliminates pain and risks associated with surgery. Examples of diseases where this treatment is used include osteoarthritis, rheumatoid arthritis, and so on. Researchers and physicians have rated this procedure to be the future of joint therapy.

Losing a tooth as a kid isnt news because youd eventually grow them back, but losing one as an adult isnt a pleasant experience. Youd have to go through the pains of getting a replacement from your dentist. Apart from the cost of these procedures, the pain and number of days youd have to stay at home nursing the pain is also a problem. Nevertheless, there are great teeth replacement therapies available for all kinds of dental problems. Although there are already good dental treatment methods, stem cell therapy might soon become the future of dental procedures. Currently, a lot of research is being done on how stem cells can be used to develop teeth naturally, especially in patients with dental problems. The aim of the project is to develop a method whereby peoples stem cells are used in regenerating their own teeth and within the shortest time possible. Some of the benefits of the stem cell tooth would be:

The quality of life of those that underwent serious procedures, especially those that had an allogeneic hematopoietic stem cell transplantation done was studied. It was discovered that this set of people had to cope with some psychological problems, even years after the procedure. In addition, allogeneic stem cell transplantation often comes with some side effects. However, this a small price to pay, considering that the adverse effects are not usually life-threatening. Also theses types of procedures are used for severe disorders or even terminal diseases. On the other hand, autologous stem cell transplantation bears the minimum to no side effects. Patients do have a great quality of life, both in the short term and in the long term.

This is one of the many uses of stem cells. The stem cell gun is a device that is used in treating people with wounds or burns. This is done by simply triggering it, and it sprays stem cells on the affected part. This kind of treatment is crucial for victims of a severe burn. Usually, people affected by severe burns would have to endure excruciating pain. The process of recovery is usually long, which might vary from weeks to months, depending on the severity of the burn. Even after treatment, most patients are left with scars forever. However, the stem cell gun eliminates these problems, the skin can be grown back in just a matter of days. The new skin also grows evenly and blends perfectly with the other part of the body. This process is also without the scars that are usually associated with the traditional burns therapy. The stem cell gun is without any side effects.

There is one company that focuses on the production of stem cell supplements. These stem cells are usually natural ingredients that increase the development of stem cells, and also keeps them healthy. The purpose of the stem cell supplements is to help reduce the aging process and make people look younger. These supplements work by replacing the dead or repairing the damaged tissues of the body. There have been a lot of testimonials to the efficacy of these supplements.

It is the goal of researchers to make stem cell therapy a good alternative for the millions of patients suffering from cardiac-related diseases. According to some experiments carried out in animals, stem cells were injected into the ones affected by heart diseases. A large percentage of them showed great improvement, even within just a few weeks. However, when the trial was carried out in humans, some stem cells went ahead to develop into heart muscles, but overall, the heart function was generally improved. The reason for the improvement has been attributed to the formation of new vessels in the heart. The topic that has generated a lot of arguments have been what type of cells should be used in the treatment of heart disorders. Stem cells extracted from the bone marrow, embryo have been in use, although bone marrow stem cells are the most commonly used. Stem cells extracted from bone marrow can differentiate into cardiac cells, while studies have shown that other stem cells cannot do the same. Even though the stem cell therapy has a lot of potential in the future, more research and studies have to be done to make that a reality.

The use of stem cells for the treatment of hair loss has increased significantly. This can be attributed to the discovery of stem cells in bone marrow, adipose cells, umbilical cord, and so on. Stem cells are extracted from the patient, through any of the sources listed above. Adipose tissue stem cells are usually the most convenient in this scenario, as they do not require any special extraction procedure. Adipose tissue is harvested from the abdominal area. The stem cells are then isolated from the other cells through a process known as centrifugation. The stem cells are then activated and are now ready for use. The isolated stem cells are then introduced into the scalp, under local anesthesia. The entire process takes about three hours. Patients are free to go home, after the procedure. Patients would begin to see improvements in just a few months, however, this depends largely on the patients ability to heal. Every patient has a different outcome.

Human umbilical stem cells are cells extracted from the umbilical cord of a healthy baby, shortly after birth. Umbilical cord tissue is abundant in stem cells, and the stem cells can differentiate into many types of cells such as red blood cells, white blood cells, and platelets. They are also capable of differentiating into non-blood cells such as muscle cells, cartilage cells and so on. These cells are usually preferred because its' extraction is minimally non invasive. It also is nearly painless. It also has zero risks of rejecting, as it does not require any form of matching or typing.Human umbilical stem cell injections are used for the treatment of spinal cord injuries. A trial was done on twenty-five patients that had late-stage spinal cord injuries. They were placed on human umbilical stem cell therapy, while another set of 25 patients were simultaneously placed on the usual rehabilitation therapy. The two groups were studied for the next twelve months. The results of the trial showed that those people placed on stem cell therapy by administering the human umbilical cell tissue injections had a significant recovery, as compared to the other group that underwent the traditional rehabilitation therapy. It was concluded that human umbilical tissue injections applied close to the injured part gives the best outcomes.

Stem cell therapy has been used for the treatment of many types diseases. This ranges from terminal illnesses such as cancer, joint diseases such as arthritis, and also autoimmune diseases. Stem cell therapy is often a better alternative to most traditional therapy today. This is because stem cell procedure is minimally invasive when compared to chemotherapy and so on. It harnesses the bodys own ability to heal. The stem cells are extracted from other parts of the body and then transplanted to other parts of the body, where they would repair and maintain the tissues. They also perform the function of modulating the immune system, which makes them important for the treatment of autoimmune diseases. Below are some of the diseases that stem cell therapies have been used successfully:

A stem cell bank can be described as a facility where stem cells are stored for future purposes. These are mostly amniotic stem cells, which are derived from the amnion fluid. Umbilical cord stem cells are also equally important as it is rich in stem cells and can be used for the treatment of many diseases. Examples of these diseases include cancer, blood disorders, autoimmune diseases, musculoskeletal diseases and so on. According to statistics, umbilical stem cells can be used for the treatment of over eighty diseases. Storing your stem cells should be seen as an investment in your health for future sake. Parents do have the option of either throwing away their babys umbilical cord or donating it to stem cell banks.

The adipose tissue contains a lot of stem cells, that has the ability to transform into other cells such as muscle, cartilage, neural cells. They are also important for the treatment of some cardiovascular diseases. This is what makes it important for people to want to store their stem cells. The future health benefit is huge. The only way adults can store their stem cells in sufficient amounts is to extract the stem cells from their fat tissues. This process is usually painless and fast. Although, the extraction might have to be done between 3 to 5 times before the needed quantity is gotten. People that missed the opportunity to store their stem cells, using their cord cells, can now store it using their own adipose tissues. This can be used at any point in time.

Side effects often accompany every kind of treatment. However, this depends largely on the individual. While patients might present with side effects, some other people wouldnt. Whether a patient will present with adverse effects, depends on the following factors;

Some of the common side effects of stem cell transplant are;

Stem cell treatment has been largely successful so far, however, more studies and research needs to be done. Stem cell therapy could be the future.

Stem cells are unique cells that have some special features such as self-regeneration, tissue repair, and modulation of the immune system. These are the features that are employed in the treatment of diseases.

Our doctors are certified by iSTEMCELL but operate as part of a medical group or as independent business owners and as such are free to charge what the feel to be the right fit for their practice and clients. We have seen Stem Cell Treatment costs range from $3500 upwards of $30,000 depending on the condition and protocol required for intended results. Find the Best Stem Cell Doctor Near me If you are interested in saving money, try our STEM CELL COUPON!

Travel Medcations are becoming very popular around the globe for several reasons but not for what one might think. It is not about traveling to Mexico to save money, but to get procedures or protocols that are not yet available in your home country. Many procedures are started in your home country, then the tissue is set to the tissue lab where it is then grown in a process to maximize live cells, then sent to a hospital in Mexico designed to treat or provide different therapies for different conditions. If you're ready to take a medical vacation call 972-800-6670 for our"WHITE GLOVE" service.

Chen, C. and Hou, J. (2016). Mesenchymal stem cell-based therapy in kidney transplantation. Stem Cell Research & Therapy, 7(1).

Donnelly, A., Johar, S., OBrien, T. and Tuan, R. (2010). Welcome to Stem Cell Research & Therapy. Stem Cell Research & Therapy, 1(1), p.1.

Groothuis, S. (2015). Changes in Stem Cell Research. Stem Cell Research, 14(1), p.130.

Rao, M. (2012). Stem cells and regenerative medicine. Stem Cell Research & Therapy, 3(4), p.27.

Vunjak-Novakovic, G. (2013). Physical influences on stem cells. Stem Cell Research & Therapy, 4(6), p.153.

View post:Stem Cell Therapy and Stem Cell Injection Provider Finder ...

View post:
New Mexico Stem Cells | Stem Cell TV

Posted in New Mexico Stem Cells | Comments Off

Stell Cell Genetics | Stem Cell TV

Posted: September 10, 2019 at 7:44 pm

Alzheimer's Disease Collaborative Group. The structure of the presenilin 1 (S182) gene and identification of six novel mutations in early onset AD families. Nature Genet. 11: 219-222, 1995. [PubMed: 7550356] [Full Text: https://dx.doi.org/10.1038/ng1095-219%5D

Ataka, S., Tomiyama, T., Takuma, H., Yamashita, T., Shimada, H., Tsutada, T., Kawabata, K., Mori, H., Miki, T. A novel presenilin-1 mutation (leu85pro) in early-onset Alzheimer disease with spastic paraparesis. Arch. Neurol. 61: 1773-1776, 2004. [PubMed: 15534188] [Full Text: https://jamanetwork.com/journals/jamaneurology/fullarticle/10.1001/archneur.61.11.1773%5D

Athan, E. S., Williamson, J., Ciappa, A., Santana, V., Romas, S. N., Lee, J. H., Rondon, H., Lantigua, R. A., Medrano, M., Torres, M., Arawaka, S., Rogaeva, E., and 10 others. A founder mutation in presenilin 1 causing early-onset Alzheimer disease in unrelated Caribbean Hispanic families. JAMA 286: 2257-2263, 2001. [PubMed: 11710891] [Full Text: https://jamanetwork.com/journals/jama/fullarticle/vol/286/pg/2257%5D

Bai, G., Chivatakarn, O., Bonanomi, D., Lettieri, K., Franco, L., Xia, C., Stein, E., Ma, L., Lewcock, J. W., Pfaff, S. L. Presenilin-dependent receptor processing is required for axon guidance. Cell 144: 106-118, 2011. [PubMed: 21215373] [Full Text: https://linkinghub.elsevier.com/retrieve/pii/S0092-8674(10)01375-9%5D

Bai, X., Yan, C., Yang, G., Lu, P., Ma, D., Sun, L., Zhou, R., Scheres, S. H. W., Shi, Y. An atomic structure of human gamma-secretase. Nature 525: 212-217, 2015. [PubMed: 26280335] [Full Text: https://doi.org/10.1038/nature14892%5D

Beck, J. A., Poulter, M., Campbell, T. A., Uphill, J. B., Adamson, G., Geddes, J. F., Revesz, T., Davis, M. B., Wood, N. W., Collinge, J., Tabrizi, S. J. Somatic and germline mosaicism in sporadic early-onset Alzheimer's disease. Hum. Molec. Genet. 13: 1219-1224, 2004. [PubMed: 15115757] [Full Text: https://academic.oup.com/hmg/article-lookup/doi/10.1093/hmg/ddh134%5D

Beglopoulos, V., Sun, X., Saura, C. A., Lemere, C. A., Kim, R. D., Shen, J. Reduced beta-amyloid production and increased inflammatory responses in presenilin conditional knock-out mice. J. Biol. Chem. 279: 46907-46914, 2004. [PubMed: 15345711] [Full Text: http://www.jbc.org/cgi/pmidlookup?view=long&pmid=15345711%5D

Bertoli Avella, A. M., Teruel, B. M., Llibre Rodriguez, J. J., Gomez Viera, N., Borrajero Martinez, I., Severijnen, E. A., Joosse, M., van Duijn, C. M., Heredero Baute, L., Heutink, P. A novel presenilin 1 mutation (L174M) in a large Cuban family with early onset Alzheimer disease. Neurogenetics 4: 97-104, 2002. [PubMed: 12484344]

Borchelt, D. R., Thinakaran, G., Eckman, C. B., Lee, M. K., Davenport, F., Ratovitsky, T., Prada, C.-M., Kim, G., Seekins, S., Yager, D., Slunt, H. H., Wang, R., Seeger, M., Levey, A. I., Gandy, S. E., Copeland, N. G., Jenkins, N. A., Price, D. L., Younkin, S. G, Sisodia, S. S. Familial Alzheimer's disease-linked presenilin 1 variants elevate A-beta-1-42/1-40 ratio in vitro and in vivo. Neuron 17: 1005-1013, 1996. [PubMed: 8938131] [Full Text: https://linkinghub.elsevier.com/retrieve/pii/S0896-6273(00)80230-5%5D

Bruni, A. C., Bernardi, L., Colao, R., Rubino, E., Smirne, N., Frangipane, F., Terni, B., Curcio, S. A. M., Mirabelli, M., Clodomiro, A., Di Lorenzo, R., Maletta, R., and 23 others. Worldwide distribution of PSEN1 Met146Leu mutation: a large variability for a founder mutation. Neurology 74: 798-806, 2010. [PubMed: 20164095] [Full Text: http://www.neurology.org/cgi/pmidlookup?view=long&pmid=20164095%5D

Buckler, A. J., Chang, D. D., Graw, S. L., Brook, J. D., Haber, D. A., Sharp, P. A., Housman, D. E. Exon amplification: a strategy to isolate mammalian genes based on RNA splicing. Proc. Nat. Acad. Sci. 88: 4005-4009, 1991. [PubMed: 1850845] [Full Text: http://www.pnas.org/cgi/pmidlookup?view=long&pmid=1850845%5D

Cai, D., Netzer, W. J., Zhong, M., Lin, Y., Du, G., Frohman, M., Foster, D. A., Sisodia, S. S., Xu, H., Gorelick, F. S., Greengard, P. Presenilin-1 uses phospholipase D1 as a negative regulator of beta-amyloid formation. Proc. Nat. Acad. Sci. 103: 1941-1946, 2006. [PubMed: 16449386] [Full Text: http://www.pnas.org/cgi/pmidlookup?view=long&pmid=16449386%5D

Cai, D., Zhong, M., Wang, R., Netzer, W. J., Shields, D., Zheng, H., Sisodia, S. S., Foster, D. A., Gorelick, F. S., Xu, H., Greengard, P. Phospholipase D1 corrects impaired beta-APP trafficking and neurite outgrowth in familial Alzheimer's disease-linked presenilin-1 mutant neurons. Proc. Nat. Acad. Sci. 103: 1936-1940, 2006. [PubMed: 16449385] [Full Text: http://www.pnas.org/cgi/pmidlookup?view=long&pmid=16449385%5D

Chau, D.-M., Crump, C. J., Villa, J. C., Scheinberg, D. A., Li, Y.-M. Familial Alzheimer disease presenilin-1 mutations alter the active site conformation of gamma-secretase. J. Biol. Chem. 287: 17288-17296, 2012. [PubMed: 22461631] [Full Text: http://www.jbc.org/cgi/pmidlookup?view=long&pmid=22461631%5D

Citron, M., Westaway, D., Xia, W., Carlson, G., Diehl, T., Levesque, G., Johnson-Wood, K., Lee, M., Seubert, P., Davis, A., Kholodenko, D., Motter, R., Sherrington, R., Perry, B., Yao, H., Strome, R., Lieberburg, I., Rommens, J., Kim. S., Schenk, D., Fraser, P., St George Hyslop, P., Selkoe, D. J. Mutant presenilins of Alzheimer's disease increase production of 42-residue amyloid beta-protein in both transfected cells and transgenic mice. Nature Med. 3: 67-72, 1997. [PubMed: 8986743]

Clark, R. F., Hutton, M., Talbot, C., Wragg, M., Lendon, C., Busfield, F., Han, S. W., Perez-Tur, J., Adams, M., Fuldner, R., Roberts, G., Karran, E., Hardy, J., Goate, A. The role of presenilin 1 in the genetics of Alzheimer's disease. Cold Spring Harbor Symp. Quant. Biol. 61: 551-558, 1996. [PubMed: 9246481] [Full Text: http://symposium.cshlp.org/cgi/pmidlookup?view=long&pmid=9246481%5D

Crook, R., Verkkoniemi, A., Perez-Tur, J., Mehta N., Baker, M., Houlden, H., Farrer, M., Hutton, M., Lincoln, S., Hardy, J., Gwinn, K., Somer, M., Paetau, A., Kalimo, H., Ylikoski, R., Poyhonen, M., Kucera, S., Haltia, M. A variant of Alzheimer's disease with spastic paraparesis and unusual plaques due to deletion of exon 9 of presenilin 1. Nature Med. 4: 452-455, 1998. [PubMed: 9546792]

Cruts, M., Van Broeckhoven, C. Presenilin mutations in Alzheimer's disease. Hum. Mutat. 11: 183-190, 1998. [PubMed: 9521418] [Full Text: https://doi.org/10.1002/(SICI)1098-1004(1998)11:33.0.CO;2-J%5D

Cruts, M., van Duijn, C. M., Backhovens, H., Van den Broeck, M., Wehnert, A., Serneels, S., Sherrington, R., Hutton, M., Hardy, J., St George-Hyslop, P. H., Hofman, A., Van Broeckhoven, C. Estimation of the genetic contribution of presenilin-1 and -2 mutations in a population-based study of presenile Alzheimer disease. Hum. Molec. Genet. 7: 43-51, 1998. [PubMed: 9384602]

Davis, J. A., Naruse, S., Chen, H., Eckman, C., Younkin, S., Price, D. L., Borchelt, D. R., Sisodia, S. S., Wong, P. C. An Alzheimer's disease-linked PS1 variant rescues the developmental abnormalities of PS1-deficient embryos. Neuron 20: 603-609, 1998. [PubMed: 9539132] [Full Text: https://linkinghub.elsevier.com/retrieve/pii/S0896-6273(00)80998-8%5D

De Jonghe, C., Cruts, M., Rogaeva, E. A., Tysoe, C., Singleton, A., Vanderstichele, H., Meschino, W., Dermaut, B., Vanderhoeven, I., Backhovens, H., Vanmechelen, E., Morris, C. M., Hardy, J., Rubinsztein, D. C., St George-Hyslop, P. H., Van Broeckhoven, C. Aberrant splicing in the presenilin-1 intron 4 mutation causes presenile Alzheimer's disease by increased A-beta-42 secretion. Hum. Molec. Genet. 8: 1529-1540, 1999. [PubMed: 10401002]

De Strooper, B., Annaert, W., Cupers, P., Saftig, P., Craessaerts, K., Mumm, J. S., Schroeter, E. H., Schrijvers, V., Wolfe, M. S., Ray, W. J., Goate, A., Kopan, R. A presenilin-1-dependent gamma-secretase-like protease mediates release of Notch intracellular domain. Nature 398: 518-522, 1999. [PubMed: 10206645] [Full Text: https://doi.org/10.1038/19083%5D

De Strooper, B., Saftig, P., Craessaerts, K., Vanderstichele, H., Guhde, G., Annaert, W., Von Figura, K., Van Leuven, F. Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein. Nature 391: 387-390, 1998. [PubMed: 9450754] [Full Text: https://doi.org/10.1038/34910%5D

De Strooper, B. Aph-1, Pen-2, and nicastrin with presenilin generate an active gamma-secretase complex. Neuron 38: 9-12, 2003. [PubMed: 12691659] [Full Text: https://linkinghub.elsevier.com/retrieve/pii/S0896627303002058%5D

Dermaut, B., Cruts, M., Slooter, A. J. C., Van Gestel, S., De Jonghe, C., Vanderstichele, H., Vanmechelen, E., Breteler, M. M., Hofman, A., van Duijn, C. M., Van Broeckhoven, C. The glu318-to-gly substitution in presenilin 1 is not causally related to Alzheimer disease. (Letter) Am. J. Hum. Genet. 64: 290-292, 1999. [PubMed: 9915968] [Full Text: https://linkinghub.elsevier.com/retrieve/pii/S0002-9297(07)61682-6%5D

Dermaut, B., Kumar-Singh, S., Engelborghs, S., Theuns, J., Rademakers, R., Saerens, J., Pickut, B. A., Peeters, K., van den Broeck, M., Vennekens, K., Claes, S., Cruts, M., Cras, P., Martin, J.-J., Van Broeckhoven, C., De Deyn, P. P. A novel presenilin 1 mutation associated with Pick's disease but not beta-amyloid plaques. Ann. Neurol. 55: 617-626, 2004. [PubMed: 15122701] [Full Text: https://doi.org/10.1002/ana.20083%5D

Devi, G., Fotiou, A., Jyrinji, D., Tycko, B., DeArmand, S., Rogaeva, E., Song, Y.-Q., Medieros, H., Liang, Y., Orlacchio, A., Williamson, J., St George-Hyslop, P., Mayeux, R. Novel presenilin 1 mutations associated with early onset of dementia in a family with both early-onset and late-onset Alzheimer disease. Arch. Neurol. 57: 1454-1457, 2000. [PubMed: 11030797] [Full Text: https://jamanetwork.com/journals/jamaneurology/fullarticle/vol/57/pg/1454%5D

Dineley, K. T., Xia, X., Bui, D., Sweatt, J. D., Zheng, H. Accelerated plaque accumulation, associative learning deficits, and up-regulation of alpha-7 nicotinic receptor protein in transgenic mice co-expressing mutant human presenilin 1 and amyloid precursor proteins. J. Biol. Chem. 277: 22768-22780, 2002. [PubMed: 11912199] [Full Text: http://www.jbc.org/cgi/pmidlookup?view=long&pmid=11912199%5D

Dolzhanskaya, N., Gonzalez, M. A., Sperziani, F., Stefl, S., Messing, J., Wen, G. Y., Alexov, E., Zuchner, S., Velinov, M. A novel p.Leu(381)Phe mutation in presenilin 1 is associated with very early onset and unusually fast progressing dementia as well as lysosomal inclusions typically seen in Kufs disease. J. Alzheimers Dis. 39: 23-27, 2014. [PubMed: 24121961] [Full Text: https://content.iospress.com/openurl?genre=article&id=doi:10.3233/JAD-131340%5D

Donoviel, D. B., Hadjantonakis, A.-K., Ikeda, M., Zheng, H., St George Hyslop, P., Bernstein, A. Mice lacking both presenilin genes exhibit early embryonic patterning defects. Genes Dev. 13: 2801-2810, 1999. [PubMed: 10557208] [Full Text: http://www.genesdev.org/cgi/pmidlookup?view=long&pmid=10557208%5D

Duff, K., Eckman, C., Zehr, C., Yu, X, Prada, C.-M., Perez-tur, J., Hutton, M., Buee, L., Harigaya, Y., Yager, D., Morgan, D., Gordon, M. N., Holcomb, L., Refolo, L., Zenk, B., Hardy, J., Youndkin, S. Increased amyloid-beta-42(43) in brains of mice expressing mutant presenilin 1. Nature 383: 710-713, 1996. [PubMed: 8878479] [Full Text: https://doi.org/10.1038/383710a0%5D

Esselens, C., Oorschot, V., Baert, V., Raemaekers, T., Spittaels, K., Serneels, L., Zheng, H., Saftig, P., De Strooper, B., Klumperman, J., Annaert, W. Presenilin 1 mediates the turnover of telencephalin in hippocampal neurons via an autophagic degradative pathway. J. Cell Biol. 166: 1041-1054, 2004. [PubMed: 15452145] [Full Text: http://jcb.rupress.org/cgi/pmidlookup?view=long&pmid=15452145%5D

Feng, R., Rampon, C., Tang, Y.-P., Shrom, D., Jin, J., Kyin, M., Sopher, B., Miller, M. W., Ware, C. B., Martin, G. M., Kim, S. H., Langdon, R. B., Sisodia, S. S., Tsien, J. Z. Deficient neurogenesis in forebrain-specific presenilin-1 knockout mice is associated with reduced clearance of hippocampal memory traces. Neuron 32: 911-926, 2001. Note: Erratum: Neuron 33: 313 only, 2002. [PubMed: 11738035] [Full Text: https://linkinghub.elsevier.com/retrieve/pii/S0896-6273(01)00523-2%5D

Fox, N. C., Kennedy, A. M., Harvey, R. J., Lantos, P. L., Roques, P. K., Collinge, J., Hardy, J., Hutton, M., Stevens, J. M., Warrington, E. K., Rossor, M. N. Clinicopathological features of familial Alzheimer's disease associated with the M139V mutation in the presenilin 1 gene: pedigree but not mutation specific age at onset provides evidence for a further genetic factor. Brain 120: 491-501, 1997. [PubMed: 9126060]

Francis, R., McGrath, G., Zhang, J., Ruddy, D. A., Sym, M., Apfeld, J., Nicoll, M., Maxwell, M., Hai, B., Ellis, M. C., Parks, A. L., Xu, W., Li, J., Gurney, M., Myers, R. L., Himes, C. S., Hiebsch, R., Ruble, C., Nye, J. S., Curtis, D. aph-1 and pen-2 are required for Notch pathway signaling, gamma-secretase cleavage of beta-APP, and presenilin protein accumulation. Dev. Cell 3: 85-97, 2002. [PubMed: 12110170] [Full Text: https://linkinghub.elsevier.com/retrieve/pii/S1534-5807(02)00189-2%5D

Ganguly, A., Feldman, R. M. R., Guo, M. Ubiquilin antagonizes presenilin and promotes neurodegeneration in Drosophila. Hum. Molec. Genet. 17: 293-302, 2008. [PubMed: 17947293] [Full Text: https://academic.oup.com/hmg/article-lookup/doi/10.1093/hmg/ddm305%5D

Georgakopoulos, A., Marambaud, P., Efthimiopoulos, S., Shioi, J., Cui, W., Li, H.-C., Schutte, M., Gordon, R., Holstein, G. R., Martinelli, G., Mehta, P., Friedrich, V. L., Jr., Robakis, N. K. Presenilin-1 forms complexes with the cadherin/catenin cell-cell adhesion system and is recruited to intercellular and synaptic contacts. Molec. Cell 4: 893-902, 1999. [PubMed: 10635315] [Full Text: https://linkinghub.elsevier.com/retrieve/pii/S1097-2765(00)80219-1%5D

Godbolt, A. K., Beck, J. A., Collinge, J., Garrard, P., Warren, J. D., Fox, N. C., Rossor, M. N. A presenilin 1 R278I mutation presenting with language impairment. Neurology 63: 1702-1704, 2004. [PubMed: 15534260] [Full Text: http://www.neurology.org/cgi/pmidlookup?view=long&pmid=15534260%5D

Goldman, J. S., Johnson, J. K., McElligott, K., Suchowersky, O., Miller, B. L., Van Deerlin, V. M. Presenilin 1 Glu318Gly polymorphism: interpret with caution. Arch. Neurol. 62: 1624-1627, 2005. [PubMed: 16216949] [Full Text: https://jamanetwork.com/journals/jamaneurology/fullarticle/10.1001/archneur.62.10.1624%5D

Grilli, M., Diodato, E., Lozza, G., Brusa, R., Casarini, M., Uberti, D., Rozmahel, R., Westaway, D., St George-Hyslop, P., Memo, M., Ongini, E. Presenilin-1 regulates the neuronal threshold to excitotoxicity both physiologically and pathologically. Proc. Nat. Acad. Sci. 97: 12822-12827, 2000. [PubMed: 11070093] [Full Text: http://www.pnas.org/cgi/pmidlookup?view=long&pmid=11070093%5D

Guo, M., Hong, E. J., Fernandes, J., Zipursky, S. L., Hay, B. A. A reporter for amyloid precursor protein gamma-secretase activity in Drosophila. Hum. Molec. Genet. 12: 2669-2678, 2003. [PubMed: 12944419] [Full Text: https://academic.oup.com/hmg/article-lookup/doi/10.1093/hmg/ddg292%5D

Gustafson, L., Brun, A., Englund, E., Hagnell, O., Nilsson, K., Stensmyr, M., Ohlin, A.-K., Abrahamson, M. A 50-year perspective of a family with chromosome-14-linked Alzheimer's disease. Hum. Genet. 102: 253-257, 1998. [PubMed: 9544835]

Halliday, G. M., Song, Y. J. C., Lepar, G., Brooks, W. S., Kwok, J. B., Kersaitis, C., Gregory, G., Shepherd, C. E., Rahimi, F., Schofield, P. R., Kril, J. J. Pick bodies in a family with presenilin-1 Alzheimer's disease. Ann. Neurol. 57: 139-143, 2005. [PubMed: 15622541] [Full Text: https://doi.org/10.1002/ana.20366%5D

Handler, M., Yang, X., Shen, J. Presenilin-1 regulates neuronal differentiation during neurogenesis. Development 127: 2593-2606, 2000. [PubMed: 10821758] [Full Text: http://dev.biologists.org/cgi/pmidlookup?view=long&pmid=10821758%5D

Hartmann, D. From Alzheimer's disease to skin tumors: the catenin connection. Proc. Nat. Acad. Sci. 98: 10522-10523, 2001. [PubMed: 11553799] [Full Text: http://www.pnas.org/cgi/pmidlookup?view=long&pmid=11553799%5D

Harvey, R. J., Ellison, D., Hardy, J., Hutton, M., Roques, P. K., Collinge, J., Fox, N. C., Rossor, M. N. Chromosome 14 familial Alzheimer's disease: the clinical and neuropathological characteristics of a family with a leucine-to-serine (L250S) substitution at codon 250 of the presenilin 1 gene. J. Neurol. Neurosurg. Psychiat. 64: 44-49, 1998. [PubMed: 9436726] [Full Text: http://jnnp.bmj.com/cgi/pmidlookup?view=long&pmid=9436726%5D

Heneka, M. T., Kummer, M. P., Stutz, A., Delekate, A., Schwartz, S., Vieira-Saecker, A., Griep, A., Axt, D., Remus, A., Tzeng, T.-C., Gelpi, E., Halle, A., Korte, M., Latz, E., Golenbock, D. T. NLRP3 is activated in Alzheimer's disease and contributes to pathology in APP/PS1 mice. Nature 493: 674-678, 2013. [PubMed: 23254930] [Full Text: https://doi.org/10.1038/nature11729%5D

Hsiao, K., Chapman, P., Nilsen, S., Eckman, C., Harigaya, Y., Younkin, S., Yang, F., Cole, G. Correlative memory deficits, A-beta elevation, and amyloid plaques in transgenic mice. Science 274: 99-103, 1996. [PubMed: 8810256] [Full Text: http://www.sciencemag.org/cgi/pmidlookup?view=long&pmid=8810256%5D

Hull, M., Fiebich, B. L., Dykierek, P., Schmidtke, K., Nitzsche, E., Orszagh, M., Deuschl, G., Moser, E., Schumacher, M., Lucking, C., Berger, M., Bauer, J. Early-onset Alzheimer's disease due to mutations of the presenilin-1 gene on chromosome 14: a 7-year follow-up of a patient with a mutation at codon 139. Europ. Arch. Psychiat. Clin. Neurosci. 248: 123-129, 1998. [PubMed: 9728730]

Ikeuchi, T., Sisodia, S. S. The notch ligands, delta-1 and jagged-2, are substrates for presenilin-dependent 'gamma-secretase' cleavage. J. Biol. Chem. 278: 7751-7754, 2003. [PubMed: 12551931] [Full Text: http://www.jbc.org/cgi/pmidlookup?view=long&pmid=12551931%5D

Ishikawa, A., Piao, Y.-S., Miyashita, A., Kuwano, R., Onodera, O., Ohtake, H., Suzuki, M., Nishizawa, M., Takahashi, H. A mutant PSEN1 causes dementia with Lewy bodies and variant Alzheimer's disease. Ann. Neurol. 57: 429-434, 2005. [PubMed: 15732120] [Full Text: https://doi.org/10.1002/ana.20393%5D

Jankowsky, J. L., Fadale, D. J., Anderson, J., Xu, G. M., Gonzales, V., Jenkins, N. A., Copeland, N. G., Lee, M. K., Younkin, L. H., Wagner, S. L., Younkin, S. G., Borchelt, D. R. Mutant presenilins specifically elevate the levels of the 42 residue beta-amyloid peptide in vivo: evidence for augmentation of a 42-specific gamma secretase. Hum. Molec. Genet. 13: 159-170, 2004. [PubMed: 14645205] [Full Text: https://academic.oup.com/hmg/article-lookup/doi/10.1093/hmg/ddh019%5D

Jarrett, J. T., Berger, E. P., Lansbury, P. T. The carboxy terminus of the beta amyloid protein is critical for the seeding of amyloid formation: implications for the pathogenesis of Alzheimer's disease. Biochemistry 32: 4693-4697, 1993. [PubMed: 8490014]

Johnson, K. A., Lopera, F., Jones, K., Becker, A., Sperling, R., Hilson, J., Londono, J., Siegert, I., Arcos, M., Moreno, S., Madrigal, L., Ossa, J., Pineda, N., Ardila, A., Roselli, M., Albert, M. S., Kosik, K. S., Rios, A. Presenilin-1-associated abnormalities in regional cerebral perfusion. Neurology 56: 1545-1551, 2001. [PubMed: 11402113] [Full Text: http://www.neurology.org/cgi/pmidlookup?view=long&pmid=11402113%5D

Jorgensen, P., Bus, C., Pallisgaard, N., Bryder, M., Jorgensen, A. L. Familial Alzheimer's disease co-segregates with a met146ile substitution in presenilin-1. Clin. Genet. 50: 281-286, 1996. [PubMed: 9007311] [Full Text: https://onlinelibrary.wiley.com/resolve/openurl?genre=article&sid=nlm:pubmed&issn=0009-9163&date=1996&volume=50&issue=5&spage=281%5D

Kaether, C., Capell, A., Edbauer, D., Winkler, E., Novak, B., Steiner, H., Haass, C. The presenilin C-terminus is required for ER-retention, nicastrin-binding and gamma-secretase activity. EMBO J. 23: 4738-4748, 2004. [PubMed: 15549135] [Full Text: http://emboj.embopress.org/cgi/pmidlookup?view=long&pmid=15549135%5D

Kamal, A., Almenar-Queralt, A., LeBlanc, J. F., Roberts, E. A., Goldstein, L. S. B. Kinesin-mediated axonal transport of a membrane compartment containing beta-secretase and presenilin-1 requires APP. Nature 414: 643-648, 2001. [PubMed: 11740561] [Full Text: https://doi.org/10.1038/414643a%5D

Kamal, A., Stokin, G. B., Yang, Z., Xia, C., Goldstein, L. S. Axonal transport of amyloid precursor protein is mediated by direct binding to the kinesin light chain subunit of kinesin-I. Neuron 28: 449-459, 2000. [PubMed: 11144355] [Full Text: https://linkinghub.elsevier.com/retrieve/pii/S0896-6273(00)00124-0%5D

Kang, D. E., Soriano, S., Xia, X., Eberhart, C. G., De Strooper, B., Zheng, H., Koo, E. H. Presenilin couples the paired phosphorylation of beta-catenin independent of Axin: implications for beta-catenin activation in tumorigenesis. Cell 110: 751-762, 2002. [PubMed: 12297048] [Full Text: https://linkinghub.elsevier.com/retrieve/pii/S0092867402009704%5D

Katayama, T., Imaizumi, K., Honda, A., Yoneda, T., Kudo, T., Takeda, M., Mori, K., Rozmahel, R., Fraser, P., St. George-Hyslop, P., Tohyama, M. Disturbed activation of endoplasmic reticulum stress transducers by familial Alzheimer's disease-linked presenilin-1 mutations. J. Biol. Chem. 276: 43446-43454, 2001. [PubMed: 11551913] [Full Text: http://www.jbc.org/cgi/pmidlookup?view=long&pmid=11551913%5D

Kauwe, J. S. K., Jacquart, S., Chakraverty, S., Wang, J., Mayo, K., Fagan, A. M., Holtzman, D. M., Morris, J. C., Goate, A. M. Extreme cerebrospinal fluid amyloid-beta levels identify family with late-onset Alzheimer's disease presenilin 1 mutation. Ann. Neurol. 61: 446-453, 2007. [PubMed: 17366635] [Full Text: https://doi.org/10.1002/ana.21099%5D

Kopan, R., Goate, A. A common enzyme connects Notch signaling and Alzheimer's disease. Genes Dev. 14: 2799-2806, 2000. [PubMed: 11090127] [Full Text: http://www.genesdev.org/cgi/pmidlookup?view=long&pmid=11090127%5D

Kosik, K. S., Munoz, C., Lopez, L., Arcila, M. L., Garcia, G., Madrigal, L., Moreno, S., Rios Romenets, S., Lopez, H., Gutierrez, M., Langbaum, J. B., Cho, W., Suliman, S., Tariot, P., Ho, C., Reiman, E. M., Lopera, F. Homozygosity of the autosomal dominant Alzheimer disease presenilin 1 E280A mutation. Neurology 84: 206-208, 2015. [PubMed: 25471389] [Full Text: http://www.neurology.org/cgi/pmidlookup?view=long&pmid=25471389%5D

Kounnas, M. Z., Danks, A. M., Cheng, S., Tyree, C., Ackerman, E., Zhang, X., Ahn, K., Nguyen, P., Comer, D., Mao, L., Yu, C., Pleynet, D., and 9 others. Modulation of gamma-secretase reduces beta-amyloid deposition in a transgenic mouse model of Alzheimer's disease. Neuron 67: 769-780, 2010. [PubMed: 20826309] [Full Text: https://linkinghub.elsevier.com/retrieve/pii/S0896-6273(10)00628-8%5D

Kovacs, D. M., Fausett, H. J., Page, K. J., Kim, T.-W., Moir, R. D., Merriam, D. E., Hollister, R. D., Hallmark, O. G., Mancini, R., Felsenstein, K. M., Hyman, B. T., Tanzi, R. E., Wasco, W. Alzheimer-associated presenilins 1 and 2: neuronal expression in brain and localization to intracellular membranes in mammalian cells. Nature Med. 2: 224-229, 1996. [PubMed: 8574969]

Kumar-Singh, S., Theuns, J., Van Broeck, B., Pirici, D., Vennekens, K., Corsmit, E., Cruts, M., Dermaut, B., Wang, R., Van Broeckhoven, C. Mean age-of-onset of familial Alzheimer disease caused by presenilin mutations correlates with both increased A-beta-42 and decreased A-beta-40. Hum. Mutat. 27: 686-695, 2006. [PubMed: 16752394] [Full Text: https://doi.org/10.1002/humu.20336%5D

Kwok, J. B. J., Halliday, G. M., Brooks, W. S., Dolios, G., Laudon, H., Murayama, O., Hallupp, M., Badenhop, R. F., Vickers, J., Wang, R., Naslund, J., Takashima, A., Gandy, S. E., Schofield, P. R. Presenilin-1 mutation L271V results in altered exon 8 splicing and Alzheimer's disease with non-cored plaques and no neuritic dystrophy. J. Biol. Chem. 278: 6748-6754, 2003. [PubMed: 12493737] [Full Text: http://www.jbc.org/cgi/pmidlookup?view=long&pmid=12493737%5D

Kwok, J. B. J., Taddei, K., Hallupp, M., Fisher, C., Brooks, W. S., Broe, G. A., Hardy, J., Fulham, M. J., Nicholson, G. A., Stell, R., St. George Hyslop, P. H., Fraser, P. E., and 6 others. Two novel (M233T and R278T) presenilin-1 mutations in early-onset Alzheimer's disease pedigrees and preliminary evidence for association of presenilin-1 mutations with a novel phenotype. Neuroreport 8: 1537-1542, 1997. [PubMed: 9172170] [Full Text: http://Insights.ovid.com/pubmed?pmid=9172170%5D

Lambert, J.-C., Mann, D. M. A., Harris, J. M., Chartier-Harlin, M.-C., Cumming, A., Coates, J., Lemmon, H., StClair, D., Iwatsubo, T., Lendon, C. The -48 C/T polymorphism in the presenilin 1 promoter is associated with an increased risk of developing Alzheimer's disease and an increased A-beta load in brain. J. Med. Genet. 38: 353-355, 2001. [PubMed: 11389157] [Full Text: http://jmg.bmj.com/cgi/pmidlookup?view=long&pmid=11389157%5D

Landman, N., Jeong, S. Y., Shin, S. Y., Voronov, S. V., Serban, G., Kang, M. S., Park, M. K., Di Paolo, G., Chung, S., Kim, T.-W. Presenilin mutations linked to familial Alzheimer's disease cause an imbalance in phosphatidylinositol 4,5-bisphosphate metabolism. Proc. Nat. Acad. Sci. 103: 19524-19529, 2006. [PubMed: 17158800] [Full Text: http://www.pnas.org/cgi/pmidlookup?view=long&pmid=17158800%5D

Laudon, H., Hansson, E. M., Melen, K., Bergman, A., Farmery, M. R., Winblad, B., Lendahl, U., von Heijne, G., Naslund, J. A nine-transmembrane domain topology for presenilin 1. J. Biol. Chem. 280: 35352-35360, 2005. [PubMed: 16046406] [Full Text: http://www.jbc.org/cgi/pmidlookup?view=long&pmid=16046406%5D

Lazarov, O., Robinson, J., Tang, Y.-P., Hairston, I. S., Korade-Mirnics, Z., Lee, V. M.-Y., Hersh, L. B., Sapolsky, R. M., Mirnics, K., Sisodia, S. S. Environmental enrichment reduces A-beta levels and amyloid deposition in transgenic mice. Cell 120: 701-713, 2005. [PubMed: 15766532] [Full Text: https://linkinghub.elsevier.com/retrieve/pii/S0092-8674(05)00089-9%5D

Lee, S.-F., Shah, S., Li, H., Yu, C., Han, W., Yu, G. Mammalian APH-1 interacts with presenilin and nicastrin and is required for intramembrane proteolysis of amyloid-beta precursor protein and Notch. J. Biol. Chem. 277: 45013-45019, 2002. [PubMed: 12297508] [Full Text: http://www.jbc.org/cgi/pmidlookup?view=long&pmid=12297508%5D

Leissring, M. A., Akbari, Y., Fanger, C. M., Cahalin, M. D., Mattson, M. P., LaFerla, F. M. Capacitative calcium entry deficits and elevated luminal calcium content in mutant presenilin-1 knockin mice. J. Cell Biol. 149: 793-797, 2000. [PubMed: 10811821] [Full Text: http://jcb.rupress.org/cgi/pmidlookup?view=long&pmid=10811821%5D

Lemere, C. A., Lopera, F., Kosik, K. S., Lendon, C. L., Ossa, J., Saido, T. C., Yamaguchi, H., Ruiz, A., Martinez, A., Madrigal, L., Hincapie, L., Arango, J. C., Anthony, D. C., Koo, E. H., Goate, A. M., Selkoe, D. J., Arango, J. C. The E280A presenilin 1 Alzheimer mutation produces increased A-beta-42 deposition and severe cerebellar pathology. Nature Med. 2: 1146-1150, 1996. [PubMed: 8837617]

Lewis, P. A., Perez-Tur, J., Golde, T. E., Hardy, J. The presenilin 1 C92S mutation increases A-beta-42 production. Biochem. Biophys. Res. Commun. 277: 261-263, 2000. [PubMed: 11027672] [Full Text: https://linkinghub.elsevier.com/retrieve/pii/S0006-291X(00)93646-5%5D

Li, D., Parks, S. B., Kushner, J. D., Nauman, D., Burgess, D., Ludwigsen, S., Partain, J., Nixon, R. R., Allen, C. N., Irwin, R. P., Jakobs, P. M., Litt, M., Hershberger, R. E. Mutations of presenilin genes in dilated cardiomyopathy and heart failure. Am. J. Hum. Genet. 79: 1030-1039, 2006. [PubMed: 17186461] [Full Text: https://linkinghub.elsevier.com/retrieve/pii/S0002-9297(07)63465-X%5D

Li, J., Xu, M., Zhou, H., Ma, J., Potter, H. Alzheimer presenilins in the nuclear membrane, interphase kinetochores, and centrosomes suggest a role in chromosome segregation. Cell 90: 917-927, 1997. [PubMed: 9298903] [Full Text: https://linkinghub.elsevier.com/retrieve/pii/S0092-8674(00)80356-6%5D

Li, Y.-M., Xu, M., Lai, M.-T., Huang, Q., Castro, J. L., DiMuzio-Mower, J., Harrison, T., Lellis, C., Nadin, A., Neduvelil, J. G., Register, R. B., Sardana, M. K., Shearman, M. S., Smith, A. L., Shi, X.-P., Yin, K.-C., Shafer, J. A., Gardell, S. J. Photoactivated gamma-secretase inhibitors directed to the active site covalently label presenilin 1. Nature 405: 689-694, 2000. [PubMed: 10864326] [Full Text: https://doi.org/10.1038/35015085%5D

Lleo, A., Berezovska, O., Herl, L., Raju, S., Deng, A., Bacskai, B. J., Frosch, M. P., Irizarry, M., Hyman, B. T. Nonsteroidal anti-inflammatory drugs lower A-beta-42 and change presenilin 1 conformation. Nature Med. 10: 1065-1066, 2004. [PubMed: 15448688] [Full Text: https://dx.doi.org/10.1038/nm1112%5D

Lopera, F., Ardilla, A., Martinez, A., Madrigal, L., Arango-Viana, J. C., Lemere, C. A., Arango-Lasprilla, J. C., Hincapie, L., Arcos-Burgos, M., Ossa, J. E., Behrens, I. M., Norton, J., Lendon, C., Goate, A. M., Ruiz-Linares, A., Rosselli, M., Kosik, K. S. Clinical features of early-onset Alzheimer disease in a large kindred with an E280A presenilin-1 mutation. JAMA 277: 793-799, 1997. [PubMed: 9052708] [Full Text: https://jamanetwork.com/journals/jama/fullarticle/vol/277/pg/793%5D

Lu, P., Bai, X., Ma, D., Xie, T., Yan, C., Sun, L., Yang, G., Zhao, Y., Zhou, R., Scheres, S. H. W., Shi, Y. Three-dimensional structure of human gamma-secretase. Nature 512: 166-170, 2014. [PubMed: 25043039] [Full Text: https://doi.org/10.1038/nature13567%5D

Marambaud, P., Wen, P. H., Dutt, A., Shioi, J., Takeshima, A., Siman, R., Robakis, N. K. A CBP binding transcriptional repressor produced by the PS1/epsilon-cleavage of N-cadherin is inhibited by PS1 FAD mutations. Cell 114: 635-645, 2003. [PubMed: 13678586] [Full Text: https://linkinghub.elsevier.com/retrieve/pii/S0092867403006512%5D

Matsubara-Tsutsui, M., Yasuda, M., Yamagata, H., Nomura, T., Taguchi, K., Kohara, K., Miyoshi, K., Miki, T. Molecular evidence of presenilin 1 mutation in familial early onset dementia. Am. J. Med. Genet. 114: 292-298, 2002. [PubMed: 11920851] [Full Text: https://onlinelibrary.wiley.com/resolve/openurl?genre=article&sid=nlm:pubmed&issn=0148-7299&date=2002&volume=114&issue=3&spage=292%5D

Mercken, M., Takahashi, H., Honda, T., Sato, K., Murayama, M., Nakazato, Y., Noguchi, K., Imahori, K., Takashima, A. Characterization of human presenilin 1 using N-terminal specific monoclonal antibodies: evidence that Alzheimer mutations affect proteolytic processing. FEBS Lett. 389: 297-303, 1996. [PubMed: 8766720] [Full Text: https://linkinghub.elsevier.com/retrieve/pii/0014-5793(96)00608-4%5D

Moehlmann, T., Winkler, E., Xia, X., Edbauer, D., Murrell, J., Capell, A., Kaether, C., Zheng, H., Ghetti, B., Haass, C., Steiner, H. Presenilin-1 mutations of leucine 166 equally affect the generation of the Notch and APP intracellular domains independent of their effect on A-beta(42) production. Proc. Nat. Acad. Sci. 99: 8025-8030, 2002. [PubMed: 12048239] [Full Text: http://www.pnas.org/cgi/pmidlookup?view=long&pmid=12048239%5D

Moonis, M., Swearer, J. M., Dayaw, M. P. E., St. George-Hyslop, P., Rogaeva, E., Kawarai, T., Pollen, D. A. Familial Alzheimer disease: decreases in CSF amyloid-beta-42 levels precede cognitive decline. Neurology 65: 323-325, 2005. [PubMed: 16043812] [Full Text: http://www.neurology.org/cgi/pmidlookup?view=long&pmid=16043812%5D

Morelli, L., Prat, M. I., Levy, E., Mangone, C. A., Castano, E. M. Presenilin 1 met146leu variant due to an A-T transversion in an early-onset familial Alzheimer's disease pedigree from Argentina. Clin. Genet. 53: 469-473, 1998. [PubMed: 9712537] [Full Text: https://onlinelibrary.wiley.com/resolve/openurl?genre=article&sid=nlm:pubmed&issn=0009-9163&date=1998&volume=53&issue=6&spage=469%5D

Moretti, P., Lieberman, A. P., Wilde, E. A., Giordani, B. I., Kluin, K. J., Koeppe, R. A., Minoshima, S., Kuhl, D. E., Seltzer, W. K., Foster, N. L. Novel insertional presenilin 1 mutation causing Alzheimer disease with spastic paraparesis. Neurology 62: 1865-1868, 2004. [PubMed: 15159497] [Full Text: http://www.neurology.org/cgi/pmidlookup?view=long&pmid=15159497%5D

Morgan, D., Diamond, D. M., Gottschall, P. E., Ugen, K. E., Dickey, C., Hardy, J., Duff, K., Jantzen, P., DiCarlo, G., Wilcock, D., Connor, K., Hatcher, J., Hope, C., Gordon, M., Arendash, G. W. A-beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature 408: 982-985, 2000. Note: Erratum Nature 412: 660 only, 2001. [PubMed: 11140686] [Full Text: https://doi.org/10.1038/35050116%5D

Murrell, J., Ghetti, B., Cochran, E., Macias-Islas, M. A., Medina, L., Varpetian, A., Cummings, J. L., Mendez, M. F., Kawas, C., Chui, H., Ringman, J. M. The A431E mutation in PSEN1 causing familial Alzheimer's disease originating in Jalisco state, Mexico: an additional fifteen families. (Letter) Neurogenetics 7: 277-279, 2006. [PubMed: 16897084] [Full Text: https://dx.doi.org/10.1007/s10048-006-0053-1%5D

Ni, C.-Y., Murphy, M. P., Golde, T. E., Carpenter, G. Gamma-secretase cleavage and nuclear localization of ErbB-4 receptor tyrosine kinase. Science 294: 2179-2181, 2001. [PubMed: 11679632] [Full Text: http://www.sciencemag.org/cgi/pmidlookup?view=long&pmid=11679632%5D

Nielsen, A. L., Holm, I. E., Johansen, M., Bonven, B., Jorgensen, P., Jorgensen, A. L. A new splice variant of glial fibrillary acidic protein, GFAP-epsilon, interacts with the presenilin proteins. J. Biol. Chem. 277: 29983-29991, 2002. [PubMed: 12058025] [Full Text: http://www.jbc.org/cgi/pmidlookup?view=long&pmid=12058025%5D

Nornes, S., Newman, M., Verdile, G., Wells, S., Stoick-Cooper, C. L., Tucker, B., Frederich-Sleptsova, I., Martins, R., Lardelli, M. Interference with splicing of presenilin transcripts has potent dominant negative effects on presenilin activity. Hum. Molec. Genet. 17: 402-412, 2008. [PubMed: 17981814] [Full Text: https://academic.oup.com/hmg/article-lookup/doi/10.1093/hmg/ddm317%5D

Norton, J. B., Cairns, N. J., Chakraverty, S., Wang, J., Levitch, D., Galvin, J. E., Goate, A. Presenilin-1 G217R mutation linked to Alzheimer disease with cotton wool plaques. Neurology 73: 480-482, 2009. [PubMed: 19667325] [Full Text: http://www.neurology.org/cgi/pmidlookup?view=long&pmid=19667325%5D

O'Riordan, S., McMonagle, P., Janssen, J. C., Fox, N. C., Farrell, M., Collinge, J., Rossor, M. N., Hutchinson, M. Presenilin-1 mutation (E280G), spastic paraparesis, and cranial MRI white-matter abnormalities. Neurology 59: 1108-1110, 2002. [PubMed: 12370477] [Full Text: http://www.neurology.org/cgi/pmidlookup?view=long&pmid=12370477%5D

Page, K., Hollister, R., Tanzi, R. E., Hyman, B. T. In situ hybridization analysis of presenilin 1 mRNA in Alzheimer disease and in lesioned rat brain. Proc. Nat. Acad. Sci. 93: 14020-14024, 1996. [PubMed: 8943053] [Full Text: http://www.pnas.org/cgi/pmidlookup?view=long&pmid=8943053%5D

Parimoo, S., Patanjali, S. R., Shukla, H., Chaplin, D. D., Weissman, S. M. cDNA selection: efficient PCR approach for the selection of cDNAs encoded in large chromosomal DNA fragments. Proc. Nat. Acad. Sci. 88: 9623-9627, 1991. [PubMed: 1946377] [Full Text: http://www.pnas.org/cgi/pmidlookup?view=long&pmid=1946377%5D

Pasternak, S. H., Bagshaw, R. D., Guiral, M., Zhang, S., Ackerley, C. A., Pak, B. J., Callahan, J. W., Mahuran, D. J. Presenilin-1, nicastrin, amyloid precursor protein, and gamma-secretase activity are co-localized in the lysosomal membrane. J. Biol. Chem. 278: 26687-26694, 2003. [PubMed: 12736250] [Full Text: http://www.jbc.org/cgi/pmidlookup?view=long&pmid=12736250%5D

Pastor, P., Roe, C. M., Villegas, A., Bedoya, G., Chakraverty, S., Garcia, G., Tirado, V., Norton, J., Rios, S., Martinez, M., Kosik, K. S., Lopera, F., Goate, A. M. Apolipoprotein E-epsilon-4 modifies Alzheimer's disease onset in an E280A PS1 kindred. Ann. Neurol. 54: 163-169, 2003. [PubMed: 12891668] [Full Text: https://doi.org/10.1002/ana.10636%5D

Link:
Stell Cell Genetics | Stem Cell TV

Posted in Stell Cell Genetics | Comments Off

Search Results for: www stemcell tv

StemCellTV Daily Report-January 24, 2012 – Video

StemCellTV Talks to Morrie Ruffin of Alliance for Regenerative Medicine at Meeting on the Mesa – Video

StemCellTV Talks to Elona Baum of the California Institute of Regenerative Medicine – Video

StemCellTV Talks to Morrie Ruffin of Alliance for Regenerative Medicine at Meeting on the Mesa – Video

StemCellTV Talks to Elona Baum of the California Institute of Regenerative Medicine – Video

StemCellTV Talks to Michael Werner of Alliance for Regenerative Medicine at Meeting on the Mesa – Video

StemCellTV Report – Bartolo Colon Stem Cell Treatment on NBC News Miami – Video

Alabama Stem Cells | Stem Cell TV

New Mexico Stem Cells | Stem Cell TV

Stell Cell Genetics | Stem Cell TV

Categories

Archives

Recommended Sites

Contact Us

Recent Posts